Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins
Diabetes, Obesity and Metabolism · 2023-12 · 25 (12) · 3817-3825
DOI: 10.1111/dom.15281 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.09.2023. Verfasst von Wei Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gan & Lee Pharmaceuticals, Beijing, China. Hauptthemen laut MEDLINE: Insulin, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Aim
For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the European Union and the United States.
Methods
Three phase 1, randomized, double‐blind, three‐period crossover trials compared single doses of the proposed biosimilar insulin analogues aspart (GL‐Asp, n = 36), lispro (GL‐Lis, n = 38) and glargine (GL‐Gla, n = 113), all manufactured by Gan & Lee pharmaceuticals, to the respective EU‐ and US‐reference products in healthy male participants (GL‐Asp and GL‐Lis) or people with type 1 diabetes (GL‐Gla). Study participants received 0.2 U/kg (aspart and lispro) or 0.5 U/kg (glargine) of each treatment under automated euglycaemic clamp conditions. The clamp duration was 12 h (aspart and lispro) or 30 h (glargine). Primary PK endpoints were the total area under the PK curves (AUC ins.total ) and maximum insulin concentrations (C ins.max ). Primary PD endpoints were the total area under the glucose infusion rate curve (AUC GIR.total ) and maximum glucose infusion rate (GIR max ).
Results
Bioequivalence to both EU‐ and US‐reference products were shown for all three GL insulins. Least squares mean ratios for the primary PK/PD endpoints were close to 100%, and both 90% and 95% confidence intervals were within 80%–125% in all three studies. There were no noticeable differences in the safety profiles between test and reference insulins, and no serious adverse events were reported for the GL insulins.
Conclusion
GL‐Asp, GL‐Lis and GL‐Gla are bioequivalent to their EU‐ and US‐reference products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gan & Lee Pharmaceuticals, Beijing, China.
- Gan & Lee Pharmaceuticals US Corporations, Bridgewater, New Jersey, USA.
- Profil, Neuss, Germany.
ORCID-Profile: Grit Andersen, Eric Zijlstra, Anshun He, Tim Heise
Zitieren
APA
Chen, W., Lu, J., Plum-Mörschel, L., Andersen, G., Zijlstra, E., He, A., Xie, T., Li, L., Hao, C., Gan, Z., & Heise, T. (2023). Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins. Diabetes, Obesity and Metabolism, 25(12), 3817-3825. https://doi.org/10.1111/dom.15281
Vancouver
Chen W, Lu J, Plum-Mörschel L, Andersen G, Zijlstra E, He A, et al. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins. Diabetes, Obesity and Metabolism. 2023;25(12):3817-3825. doi:10.1111/dom.15281
BibTeX
@article{Chen2023,
author = {Chen, Wei and Lu, Jia and Plum-Mörschel, Leona and Andersen, Grit and Zijlstra, Eric and He, Anshun and Xie, Tian and Li, Longling and Hao, Chunyue and Gan, Zhongru and Heise, Tim},
title = {Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {12},
pages = {3817--3825},
doi = {10.1111/dom.15281}
}
EUVIMED